SpringerLink
Log in

Multimodale Therapiekonzepte bei fernmetastasierten differenzierten Schilddrüsenkarzinomen

  • Living reference work entry
  • First Online:
Viszeral- und Allgemeinchirurgie

Part of the book series: Springer Reference Medizin ((SRM))

  • 66 Accesses

Zusammenfassung

Das Auftreten von Fernmetastasen beim differenzierten Schilddrüsenkarzinom (DTC), welche sich bevorzugt pulmonal und ossär finden, ist selten.

Das Therapiekonzept richtet sich individuell nach dem Allgemeinzustand, weiteren relevanten Erkrankungen, dem Metastasierungsmuster sowie der Metastasenlast und der Krankheitsdynamik. Die primäre therapeutische Option bei fernmetastasierten DTC ist die Radiojodtherapie. Etablierte Konzepte umfassen zudem die TSH-suppressive Therapie, Metastasenchirurgie, externe Bestrahlungen, lokale Ablationen oder eine Therapie mit Tyrosinkinase-Inhibitoren (TKI). TKI sind eine relativ neue Klasse kleinmolekularer Medikamente. Der Zeitpunkt für einen Beginn mit einer TKI-Therapie ist Gegenstand aktueller Diskussionen, da die beschriebenen therapieassoziierten Toxizitäten schwerwiegend sein können und die Lebensqualität nachhaltig beeinträchtigen. Die Lebensqualität von Patienten mit Schilddrüsenkarzinomen ist niedriger als im Bevölkerungsdurchschnitt. Manche Patienten leiden unter Müdigkeit und Depression.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Similar content being viewed by others

Literatur

  • Beak JH, Kim YS, Sung JY et al (2011) Locoregional control of metastatic well-differentiated thyroid cancer by ultrasound-guided radiofrequency ablation. AJR Am J Roentgenol 197(2):W331–W336

    Article  Google Scholar 

  • Benua RS, Cicale NR, Sonenberg M et al (1962) The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgenol Radium Therapy, Nucl Med 87:171e82

    Google Scholar 

  • Berdelou A, Borget I, Godbert Y et al (2017) Lenvatinib for the treatment of radioiodine-refractory thyroid cancer in real-life practice. Thyroid. https://doi.org/10.1089/thy.2017.0205

  • Bernier MO, Leenhardt L, Hoang C et al (2001) Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas. J Clin Endocrinol Metab 86:1568–1573

    Article  CAS  PubMed  Google Scholar 

  • Brose MS, Nutting CM, Jarzab B et al (2014) Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 384:319–328

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bruglia M, Palmonella G, Silvetti F et al (2009) Skin and thigh muscle metastasis from papillary thyroid cancer. Singap Med J 50:e61–e64

    CAS  Google Scholar 

  • Cabanillas ME, Takahashi S (2019) Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer. Semin Oncol 46(1):57–64

    Article  CAS  PubMed  Google Scholar 

  • Chen P, Feng HJ, Ouyang W et al (2016) Risk factors for nonremission and progression-free survival after I-131 therapy in patients with lung metastases from differentiated thyroid cancer: a single-institute, retrospective analysis in southern china. Endocr Pract 22(9):1048–1056

    Article  PubMed  Google Scholar 

  • Davidson M, Olsen RJ, Ewton AA et al (2017) Pancreas metastases from papillary thyroid carcinoma: a review of the literature. Endocr Pract 23(12):1425–1429

    Article  PubMed  Google Scholar 

  • Diessl S, Holzberger B, Mäder U et al (2012) Impact of moderate vs stringent TSH suppression on survival in advanced differentiated thyroid carcinoma. Clin Endocrinol 76(4):586–592

    Article  CAS  Google Scholar 

  • Dietlein M, Eschner W, Grünwald F, et al (2015) Radioiodtherapie beim differenzierten Schilddrüsenkarzinom (Version4). DGN-Handlungsempfehlung S1-Leitlinie; Stand 10/2015; AWMF-Registernummer:031-002

    Google Scholar 

  • Doebele RC, Drilon A, Paz-Ares L et al (2020) Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Lancet Oncol 21:271–282

    Article  CAS  PubMed  Google Scholar 

  • Drilon A, Laetsch TW, Kummar S et al (2018) Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 378:731–739

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Dupuy DE, Monchik JM, Decrea C et al (2001) Radiofrequency ablation of regional recurrence from well-differentiated thyroid malignancy. Surgery 130:971–977

    Article  CAS  PubMed  Google Scholar 

  • Durante C, Haddy N, Leboulleux S et al (2006) Long-term outcome of 444 patients with distant metastases from papilary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 91(8):2892–2899

    Article  CAS  PubMed  Google Scholar 

  • Eustatia-Rutten CF, Romijn JA, Guijt MJ et al (2003) Outcome of palliative embolization of bone metastases in differentiated thyroid carconoma. J Clin Endocrinol Metab 88:3184–3189

    Article  CAS  PubMed  Google Scholar 

  • Fard-Esfahani A, Emami-Ardekani A, Fallahi B et al (2014) Adverse effects of radioactive iodine-131 treatment for differentiated thyroid carcinoma. Nucl Med Commun 35(8):808–817

    Article  CAS  PubMed  Google Scholar 

  • Fassnacht M, Kreissl MC, Weismann D et al (2009) New targets and therapeutic approaches for endocrine malignancies. Pharmacol Ther 123(1):117–141

    Article  CAS  PubMed  Google Scholar 

  • Felicetti F, Nervo A, Piovesan A et al (2017) Tyrosine kinase inhibitors rechallenge in solid tumors: a review of literature and a case description with lenvatinib in thyroid cancer. Expert Rev Anticancer Ther 17(12):1093–1098

    Article  CAS  PubMed  Google Scholar 

  • Gomez Hernandez K, Hafezi-Bakhtiari S, Pierre A et al (2014) Metastatic thyroid carcinoma to the gastric body. J Clin Endocrinol Metab 99:3958–3959

    Article  PubMed  CAS  Google Scholar 

  • Grimm MO, Spiegelhalder P, Heep H et al (2004) Penile metastasis secondary to follicular thyroid carcinoma. Scand J Urol Nephrol 38:253–255

    Article  PubMed  Google Scholar 

  • Guang Y, Luo Y, Zhang Y et al (2017) Efficacy and safety of percutaneous ultrasound guided radiofrequency ablation for treating cervical metastatic lymph nodes from papillary thyroid carcinoma. J Cancer Res Clin Oncol 143:1555–1562

    Article  CAS  PubMed  Google Scholar 

  • Guignier B, Naoun O, Subilia A et al (2011) Choroidal metastasis from follicular thyroid carcinoma: a rare case. J Fr Ophtalmol 34:329.e1-5

    PubMed  Google Scholar 

  • Hanna GJ, Busaidy NL, Chau NG et al (2018) Genomic correlates of response to everolimus in aggressive radiojodine-refractory thyroid cancer: a phase II study. Clin Cancer Res 24:1546–1553

    Article  CAS  PubMed  Google Scholar 

  • Haugen BR, Alexander EK, Bible KC et al (2016) 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26:1–133

    Article  PubMed  PubMed Central  Google Scholar 

  • Heilo A, Sigstad E, Fagerlid KH et al (2011) Efficacy of ultrasound-guided percutaneous ethanol injection treatment in patients with a limited number of metastastic cervical lymph nodes from papillary thyroid carcinoma. J Clin Endocrinol Metab 96:2750–2755

    Article  CAS  PubMed  Google Scholar 

  • Hunt A, Newbold KL (2019) Targeted molecular therapy. In: Luster M, Duntas LH, Wartkofsky L (Hrsg) The thyroid and its diseases. Springer, Cham, S 647–654

    Google Scholar 

  • Ito Y, Masuoka H, Fukushima M et al (2010) Prognosis and prognostic factors of patients with papillary carcinoma showing distant metastasis at surgery (M1 patients) in Japan. Endocr J 57(6):523–531

    Article  PubMed  Google Scholar 

  • Jonklaas J, Sarlis NJ, Litofsky D et al (2006) Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 16(12):1229–1242

    Article  PubMed  Google Scholar 

  • Klein-Hesselink EN, Klein-Hesselink MS, de Bock GH et al (2013) Long-term cardiovascular mortality in patients with differentiated thyroid carcinoma: an observational study. J Clin Oncol 31(32):4046–4053

    Article  PubMed  Google Scholar 

  • Klubo-Gwiezdzinska J, Van Nostrand D, Atkins F et al (2011) Efficacy of dosimetric versus empiric prescribed activity of 131I for therapy of differentiated thyroid cancer. J Clin Endocrinol Metab 96(10):3217–3225

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Knauf JA, Kuroda H, Basu S et al (2003) RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase. Oncogene 22(28):4406–4412

    Article  CAS  PubMed  Google Scholar 

  • Kreissl MC, Janssen MRJ, Nagarajah J (2019) Current treatment strategies in metastasized differentiated thyroid cancer. J Nucl Med 60:9–15

    Article  CAS  PubMed  Google Scholar 

  • Kreissl MC, Reinecke M, Luster M (2020a) Radiation risks after radioiodine therapy. Der Nuklearmediziner 43:213–217

    Google Scholar 

  • Kreissl MC, Widmann T, Genseke P et al (2020b) Update 2020: Systemische Therapie des differenzierten und medullären Schilddrüsenkarzinoms. Der Nuklearmediziner 43(03):218–224

    Article  Google Scholar 

  • Lee B, Cook G, John L, Harrington K, Nutting C (2008) Follicular thyroid carcinoma metastasis to the esophagus detected by 18FDG PET/CT. Thyroid 18:267–271

    Article  PubMed  Google Scholar 

  • Lewis BD, Hay ID, Charboneau JW et al (2002) Percutaneous ethanol injection for treatment of cervical lymph node metastases in patients with papillary thyroid carcinoma. AJR Am J Roentgenol 178:699–704

    Article  CAS  PubMed  Google Scholar 

  • Liu SV, Macke LA, Colton BS et al (2017) Response to entrectinib in differentiated thyroid cancer with a ROS1 fusion. JCO Precis Oncol 1:1–5

    Article  CAS  Google Scholar 

  • Locati LD, Piovesan A, Durante C et al (2019) Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy. Eur J Cancer 118:35–40

    Article  CAS  PubMed  Google Scholar 

  • Malhotra G, Upadhye TS, Sridhar E et al (2010) Unusual case of adrenal and renal metastases from papillary carcinoma of thyroid. Clin Nucl Med 35(9):731–736

    Article  PubMed  Google Scholar 

  • Massicotte MH, Brassard M, Claude-Desroches M et al (2014) Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network. Eur J Endocrinol 170:575–582

    Article  CAS  PubMed  Google Scholar 

  • Maxon HR, Thomas SR, Hertzberg VS et al (1983) Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med 309:937e41

    Article  Google Scholar 

  • McIntyre C, Jaques T, Palazzo F et al (2018) Quality of life in differentiated thyroid cancer. Int J Surg 50:133–136

    Article  PubMed  Google Scholar 

  • Mihailovic J, Glodsmith SJ (2019) Radioiodine therapy in differentiated thyroid cancer. In: Luster M, Duntas LH, Wartkofsky L (Hrsg) The thyroid and its diseases. Springer, Cham, S 611–632

    Google Scholar 

  • Monchik JM, Donatini G, Iannuccili J et al (2006) Radiofrequency ablation and percutaneous ethanol injection treatment for recurrent local and distant well-differentiated thyroid carcinoma. Ann Surg 244(2):296–304

    Article  PubMed  PubMed Central  Google Scholar 

  • Nagarajah J, Le M, Knauf JA et al (2016) Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine. J Clin Invest 126(11):4119–4124

    Article  PubMed  PubMed Central  Google Scholar 

  • Nakada K, Ishibashi T, Takei T et al (2005) Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer? J Nucl Med 46(2):261–266

    PubMed  Google Scholar 

  • Nimmagadda A, Krishna Mohan VS, Mantheri R et al (2019) Unusual metastases in papillary microcarcinoma of thyroid. Indian J Nucl Med 34(1):32–34

    Article  PubMed  PubMed Central  Google Scholar 

  • Nylén C, Mechera R, Maréchal-Ross I et al (2020) Molecular markers guiding thyroid cancer management. Cancers 12(8):2164

    Article  PubMed Central  CAS  Google Scholar 

  • Okamura R, Boichard A, Kato S et al (2018) Analysis of NTRK alterations in pan-cancer adult and pediatric malignancies: implications for NTRK-targeted therapeutics. JCO Precis Oncol. https://doi.org/10.1200/PO.18.00183

  • Ozpacaci T, Mulazimoglu M, Tamam MO et al (2012) Intraocular and orbital metastasis as a rare form of clinical presentation of insular thyroid cancer. Ann Endocrinol 73:222–224

    Article  Google Scholar 

  • Pacini F, Gasperi M, Fugazzola L et al (1994) Testicular function in patients with thyroid carcinoma treated with radioiodine. J Nucl Med 35:1418–1422

    CAS  PubMed  Google Scholar 

  • Pujol P, Daures JP, Nsakala N et al (1996) Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab 81:4318–4323

    CAS  PubMed  Google Scholar 

  • Reiners C (2010) Diagnostik, Therapie und Nachsorge des Schilddrüsenkarzinoms. UNI-MED, 3. Aufl. Uni-Med Verlag, Bremen-London-Boston, S 68–72

    Google Scholar 

  • Rivkees S, Mazzaferri EL, Verburg FA et al (2011) The treatment of differentiated thyroid cancer in children: emphasis on surgical approach and radioactive iodine therapy. Endocr Rev 32(6):798–826

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Samuel AM, Rajashekharrao B, Shah DH (1998) Pulmonary metastases in children and adolescents with well-differentiated thyroid cancer. J Nucl Med 39:1531–1536

    CAS  PubMed  Google Scholar 

  • Sarda AK, Pandey D, Bhalla SA et al (2004) Isolated submandibular gland metastasis from an occult papillary thyroid cancer. Indian J Cancer 41:89–91

    CAS  PubMed  Google Scholar 

  • Sawin CT, Geller A, Wolf PA et al (1994) Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 331:1249–1252

    Article  CAS  PubMed  Google Scholar 

  • Schlumberger M, Tahara M, Wirth LJ et al (2015) Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 372:621–630

    Article  PubMed  CAS  Google Scholar 

  • Sherman SI (2010) Cytotoxic chemotherapy for differentiated thyroid carcinoma. Clin Oncol (R Coll Radiol) 22(6):464–468

    Article  CAS  Google Scholar 

  • Song HJ, Xue YL, Xu YH et al (2011) Rare metastases of differentiated thyroid carcinoma: pictorial review. Endocr Relat Cancer 18(5):165–174

    Article  CAS  Google Scholar 

  • Taylor MH, Gainor JF, Hu MI-N et al (2019) Activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients with advanced RET-altered thyroid cancers. JClin Oncol 37:6018

    Google Scholar 

  • Tuttle RM, Brose MS, Grande E et al (2017) Novel concepts for initiating multitargeted kinase inhibitors in radioactive iodine refractory differentiated thyroid cancer. Best Pract Res Clin Endocrinol Metab 31:295–305

    Article  CAS  PubMed  Google Scholar 

  • Tuttle RM, Ahuja S, Avram AM et al (2019) Controversies, consensus, and collaboration in the use of 131i therapy in differentiated thyroid cancer: a joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association. Thyroid 29(4):461–470

    Article  PubMed  Google Scholar 

  • Verburg FA, Hänscheid H, Luster M (2017) Radioactive iodine (RAI) therapy for metastatic differentiated thyroid cancer. Best Pract Res Clin Endocrinol Metab 31(3):279–290

    Article  CAS  PubMed  Google Scholar 

  • Waguespack SG, Drilon A, Farago AF et al (2019) Treatment of advanced TRK fusion thyroid cancer with larotrectinib. ETA 2019

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Nuklearmedizin, Universitätsklinikum Marburg, Marburg, Deutschland

    Friederike Eilsberger & Markus Luster

Authors
  1. Friederike Eilsberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Markus Luster
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Friederike Eilsberger .

Editor information

Editors and Affiliations

  1. Allgemein- Viszeral- u. Gefäßchirurgie, Charité Universitätsmedizin Berlin, Berlin, Berlin, Deutschland

    Martin Kreis

  2. Klinik für Visceral-, Thorax- und G, Universitätsklinikum Marburg, Marburg, Hessen, Deutschland

    Detlef K. Bartsch

  3. Klinik & Poliklinik Allgemein & Abdomin, Universitätsklinikum Mainz, Mainz, Rheinland-Pfalz, Deutschland

    Hauke Lang

Section Editor information

  1. Klinik für Visceral-, Thorax- und Gefäßchirurgie, Philipps-Universität Marburg, Marburg, Deutschland

    Detlef K. Bartsch

  2. Klinik für Visceral-, Thorax- und Gefäßchirurgie, Philipps-Universität Marburg, Marburg, Deutschland

    Katharina Holzer

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Eilsberger, F., Luster, M. (2021). Multimodale Therapiekonzepte bei fernmetastasierten differenzierten Schilddrüsenkarzinomen. In: Kreis, M., Bartsch, D.K., Lang, H. (eds) Viszeral- und Allgemeinchirurgie. Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-61724-3_17-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-61724-3_17-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-61724-3

  • Online ISBN: 978-3-662-61724-3

  • eBook Packages: Springer Referenz Medizin

Publish with us

Policies and ethics

Search

Navigation